riTUXimab (subcut)
Pronunciation: rit-TUCKS-ee-mab
Other Name(s): Rituxan® SC
Appearance: Clear, colourless to yellowish solution
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
Jun 2025
Eligibility Forms
Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic LeukemiaPatient Info Sheet
Oct 2023
What it is used for
- For treating blood cancers such as non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL)